Some mergers can add a nice shot in the arm for an acquirer. After years of being focused on Humira, AbbVie has now completed its acquisition of Allergan.
Brokerage firm Canaccord Genuity issued some key takeaways on a few different companies at ASCO. 24/7 Wall St. has also included some recent data on the stock.
PhaseBio Pharmaceuticals shares jumped early on Thursday after the company announced that it received an authorization from the FDA regarding its COVID-19 treatment.
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
Diffusion Pharmaceuticals shares pushed higher to start the week after it announced a critical update from the FDA concerning its potential treatment for COVID-19 patients displaying severe...
Merck shares jumped on Tuesday after the company announced that it has made deals to develop drugs in the fight against COVID-19.
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
Navidea Biopharmaceuticals shares more than doubled to close out the week after the company provided an update from its midstage study in patients with active rheumatoid arthritis.
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
Wedbush took a closer look at some of the companies in its coverage universe that are set to present at ASCO and what the impact may be going forward.
These are five of the best stocks in a sector that has been humming along in what has been a turbulent year. They are all included on the Goldman Sachs Conviction List too.
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
BioNTech and Pfizer stocks each made a handy gain on Monday after the companies announced the beginning of human trials for a COVID-19 vaccine.
Regeneron Pharmaceuticals reported its first-quarter financial results before the markets opened on Tuesday. While the earnings were important, and fairly positive, more investors seemed interested...
Portola Pharmaceuticals shares more than doubled on Tuesday after the company announced that it would be acquired by Alexion Pharmaceuticals.